We found a statistically significant link between the FASL rs763110 polymorphism and cancer risk in studies utilizing genotyping method with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in heterozygote and dominant model comparison (TC vs. CC: OR = 0.79, 95%CI = 0.70–0.87; Pheterogeneity<0.001; dominant model: OR = 0.80, 95%CI = 0.72–0.90; Pheterogeneity<0.001), but not for studies using Taqman assay. The gene discussed is FASLG; the disease is cancer.